Redmile Group LLC Sells 21,800 Shares of Celldex Therapeutics, Inc. $CLDX

Redmile Group LLC decreased its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 7.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 261,508 shares of the biopharmaceutical company’s stock after selling 21,800 shares during the period. Celldex Therapeutics accounts for about 0.5% of Redmile Group LLC’s holdings, making the stock its 24th largest holding. Redmile Group LLC owned about 0.33% of Celldex Therapeutics worth $8,295,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Eversept Partners LP grew its position in shares of Celldex Therapeutics by 24.6% in the 1st quarter. Eversept Partners LP now owns 1,788,016 shares of the biopharmaceutical company’s stock worth $56,716,000 after buying an additional 353,291 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Celldex Therapeutics by 3.5% during the first quarter. The Manufacturers Life Insurance Company now owns 77,772 shares of the biopharmaceutical company’s stock valued at $2,467,000 after acquiring an additional 2,642 shares in the last quarter. Quantinno Capital Management LP lifted its stake in Celldex Therapeutics by 178.7% in the first quarter. Quantinno Capital Management LP now owns 65,744 shares of the biopharmaceutical company’s stock worth $2,085,000 after acquiring an additional 42,158 shares during the period. SummitTX Capital L.P. lifted its stake in Celldex Therapeutics by 446.2% in the first quarter. SummitTX Capital L.P. now owns 236,637 shares of the biopharmaceutical company’s stock worth $7,506,000 after acquiring an additional 193,313 shares during the period. Finally, Commodore Capital LP boosted its holdings in Celldex Therapeutics by 5.1% in the first quarter. Commodore Capital LP now owns 2,696,616 shares of the biopharmaceutical company’s stock valued at $85,537,000 after acquiring an additional 131,616 shares in the last quarter.

Celldex Therapeutics Stock Performance

Shares of CLDX opened at $35.58 on Wednesday. Celldex Therapeutics, Inc. has a fifty-two week low of $19.72 and a fifty-two week high of $40.30. The firm’s 50-day simple moving average is $33.86 and its two-hundred day simple moving average is $30.83. The stock has a market cap of $2.79 billion, a PE ratio of -8.35 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.80 million. Equities research analysts predict that Celldex Therapeutics, Inc. will post -4.36 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have commented on CLDX. Morgan Stanley decreased their price objective on shares of Celldex Therapeutics from $44.00 to $40.00 and set an “overweight” rating for the company in a report on Wednesday, July 22nd. Wall Street Zen raised shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. Barclays raised their price objective on shares of Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Cantor Fitzgerald reduced their target price on Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating on the stock in a report on Wednesday, July 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $42.00 target price on shares of Celldex Therapeutics in a research note on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $52.77.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.